Spinal Tech

Stryker ranks No. 16 out of 100 on Fortune Magazine's Best Companies to Work For list. Here are four insights:

The global artificial disc replacement market is set to grow at a 15 percent compound annual growth rate through 2023, based on a Market Research Future report, according to Herald Keeper.

Mazor CEO Ori Hadomi spoke on several topics during the 2017 earnings call earlier this week, including the future for both the Renaissance and Mazor X systems, according to a transcript published in Seeking Alpha. He also touched on the…

Simplify Medical concluded enrollment for its U.S. investigational device exemption trial testing the Simplify cervical artificial disc.

Enrollment is completed for Spineology's SCOUT clinical trial.

After crossing the 95 percent threshold in Vexim, Stryker plans to file a public buy-out offer followed by a squeeze-out for outstanding Vexim shares.

Here are 16 key notes on orthopedic and spine device companies from the past week.

Mazor Robotics reported full year 2017 revenue at $64.9 million, including its investment from Medtronic for Mazor X systems. Mazor has now invested around $72 million in Mazor and taken over marketing efforts for the product; the companies will develop…

Stryker named Kevin Lobo CEO in October 2012. Here are five things to know about him:

Vik Kapoor, MD, a Medovex medical advisory board member, presented initial data from his DenerveX System study.